Talus Bioscience combines functional proteomics, automated biology, and machine learning to target transcription factor proteins driving cancer and beyond.

Talus Bioscience

Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. 

Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics.

As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery:

- Developing internal programs against previously undruggable gene regulators in 
 cancers with poor standard of care
- Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs

National Science Foundation

National Institutes of Health

Andy Hill Cancer Research Endowment (CARE) Fund

Y Combinator

Fifty Years

FundersClub

Pioneer Fund

North South Ventures

Farvatn Venture

Reinforced Ventures

Talus Bio

Thanks to World Industry News for including Talus Bio on your list of notable proteomics companies!

Don’t miss this opportunity to hear a great proteomics discussion including one of the world’s leading experts, Talus Bio CTO Lindsay Pino!

What a great week at BIO 2024 in San Diego! The Talus Bio team stayed very busy with 2 company presentations, 24 partnering meetings, and countless networking receptions. It was an amazing opportunity to connect with current and potential pharma partners, investors, and scientific colleagues!

Talus Bio is getting very excited about the American Society For Mass Spectrometry (ASMS) Annual Conference that starts this weekend, and we'll be very well represented! If you're attending the conference, be sure to check out one (or all) of the great opportunities to learn more about the cutting-edge transcription factor drug discovery powered by AI being done at Talus Bio presented by William Fondrie, Lindsay Pino, Daniele Canzani, PhD, Sebastian Paez, Andrea Gutierrez, and Julia Robbins.

I'm looking forward to this!

Transforming Healthcare and Drug Discovery with Artificial Intelligence (AI)
Presenting by HBA Seattle
May 20th, 2:00 - 5:30 pm at Adaptive Biotechnologies Corp.

Speakers:
Shweta Maniar Global Director, Healthcare & Life Sciences at Google Cloud
Jeremy Forman, VP, R&D, Data, & Analytics at Pfizer (Seagen)
Kate Ostbye, Director, Enterprise Data Science and Machine Learning at Pfizer (Seagen)

Registration link: https://bit.ly/3vLZz5x

Such a great Day 1 at the Life Science Innovation Northwest conference today! Alex Federation, CEO and Co-Founder of Talus Bio gave an excellent presentation in the Oncology session. Looking forward to Day 2!

BIO:TALUS

Talus Bioscience

Analysis Not Available